Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis
Iñaki Comino‐Méndez(Breast Cancer Now), Alberto Cascón(Spanish National Cancer Research Centre), Carolina Sánchez-Malo(Medical Oncology Hematology Consultants), Guillermo Pita(Spanish National Cancer Research Centre), Aguirre A. de Cubas(Medical University of South Carolina), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), Tonino Ercolino(Azienda Ospedaliero-Universitaria Careggi), Massimo Mannelli(University of Florence), Susana Pedrinaci(Universidad de Granada), César L. Ramírez-Tortosa(Instituto de Investigación Biosanitaria de Granada), Cristina Álvarez‐Escolá(Hospital Universitario La Paz), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Álvaro Gómez-Graña(Spanish National Cancer Research Centre), Alessandra Bacca(University of Pisa), Veronika Mančíková(Centro de Biología Molecular Severo Ochoa), Lucía Inglada‐Pérez(Spanish National Cancer Research Centre), Elena Rapizzi(El.En. Group (Italy)), María R. Alonso(Spanish National Cancer Research Centre), Rocío Letón, Giampaolo Bernini(University of Pisa), Luis J. Leandro‐García(Spanish National Cancer Research Centre)
Cited by 168
Related Papers
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
|Cell Reports|2018|818
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
|Cancer Cell|2017|791
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
|Nature Genetics|2013|544
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis
|The Lancet Oncology|2009|536
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
|Nature Genetics|2011|528